TScan Therapeutics, Inc. logo

TScan Therapeutics, Inc.

NASDAQ:TCRX

Overview | Financials
Company Name TScan Therapeutics, Inc.
Symbol TCRX
Currency USD
Price 2.63
Market Cap 140,364,670
Dividend Yield 0%
52-week-range 2.6 - 9.69
Industry Biotechnology
Sector Healthcare
CEO Dr. Gavin MacBeath Ph.D.
Website https://www.tscan.com

An error occurred while fetching data.

About TScan Therapeutics, Inc.

TScan Therapeutics, Inc., a preclinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell therapies for the treatment of patients with cancer. It is developing TSC-100 and TSC-101 for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation; and TSC-200, TSC-201,

Related Stocks

Anebulo Pharmaceuticals, Inc. logo

Anebulo Pharmaceuticals, Inc.

ANEB

1.596 USD

HCW Biologics Inc. logo

HCW Biologics Inc.

HCWB

0.342 USD

Genprex, Inc. logo

Genprex, Inc.

GNPX

0.738 USD

Cardiol Therapeutics Inc. logo

Cardiol Therapeutics Inc.

CRDL

1.25 USD

Merrimack Pharmaceuticals, Inc. logo

Merrimack Pharmaceuticals, Inc.

MACK

15.145 USD

Sientra, Inc. logo

Sientra, Inc.

SIEN

0.174 USD

Minerva Surgical, Inc. logo

Minerva Surgical, Inc.

UTRS

0 USD

Galectin Therapeutics Inc. logo

Galectin Therapeutics Inc.

GALT

1.15 USD

Financials

Numbers are in millions USD

Numbers are in millions USD